Monday June 26th 2017

Archive for April, 2010

CCSVI: My Doppler Results and Plans for Treatment

CCSVI: My Doppler Results and Plans for Treatment

Yesterday I met with a Professor who is expert in cardiovascular and interventional radiology. He reviewed my scans and reports and is recommending a course of action involving inserting a catheter and balloon into the vein to open up the stenosis. [Read More]

Ben Parker Discusses MS and CCSVI

Ben Parker Discusses MS and CCSVI

Ben Parker talks about CCSVI and MS on BBC Radio Essex Posted by Eric Beauchamp [Read More]

CCSVI Who are we fighting, will you be heard?

CCSVI Who are we fighting, will you be heard?

Where is the media coverage for CCSVI, who will speak up for us, how do we get more research done as a group How do we come together? Here is a link to a petition I started www.gopetition.com www.facebook.com Huffington Post article and this vlog mentioned [Read More]

 Page 1 of 10  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]